We're BlueService... BlueService is the difference that makes the difference.

Pharmacy news

FDA issues an alert regarding counterfeit One Touch brand test strips — Read the latest news on counterfeit blood glucose test strips being sold for use with various models of LifeScan, Inc., One Touch Brand Blood Glucose Monitors used by people with diabetes to measure their blood glucose.  

FDA Consumer Magazine, May-June 2005 — Read the latest issue of an informative e-zine from the U.S. Food and Drug Administration.

FDA announces series of changes to the class of marketed non-steroidal anti-inflammatory drugs (NSAIDs) — The Food and Drug Administration (FDA) today announced a series of important changes pertaining to the marketing of the non-steroidal anti-inflammatory class of drugs, including COX-2 selective and prescription and non-prescription (over-the-counter (OTC)) non-selective NSAID medications.  Read the complete article at www.fda.gov.

FDA issues public health advisory recommending limited use of COX-2 inhibitors — The Food and Drug Administration (FDA) has issued a Public Health Advisory summarizing the agency's recent recommendations concerning the use of non-steroidal anti-inflammatory drug products (NSAIDs), including those known as COX-2 selective agents. The public health advisory is an interim measure, pending further review of data that continue to be collected. Read the complete article at www.fda.gov.

Watching computer screen too long can lead to glaucoma — If you are short sighted and spend nine hours or more each day in front of your computer screen you are significantly increasing your chances of developing glaucoma - an eye disease which can eventually make you blind. Read the complete article at www.medicalnewstoday.com 
 
FDA guidance details changes to generic drug approval process — FDA has issued guidance for industry that explains some of the steps the agency is taking to implement revisions to the generic drug approval process that are part of the recent Medicare prescription drug law. The guidance clarifies, for example, the 180-day marketing exclusivity for "first" generic drug applicants. Read the complete article at www.fda.gov

Measures announced to bolster safety evaluations for drugs — FDA has announced a series of steps aimed at strengthening the agency's program for evaluating the safety of marketed drugs. Among measures: a study of the national drug safety system by the Institute of Medicine; a program for mediating differing opinions among product reviewers; and workshops and meetings to discuss complex drug safety and risk management issues. Read the complete article at www.fda.gov